

Supplemental Information for:

8-azaadenosine and 8-chloroadenosine are not selective inhibitors of ADAR

Kyle A. Cottrell¹, Luisangely Soto Torres¹, Michael G. Dizon¹, Jason D. Weber^{1,2,*}

¹Department of Medicine, Division of Molecular Oncology and ²Department of Cell Biology and Physiology, Siteman Cancer Center, Washington University School of Medicine, Saint Louis, Missouri, USA

*Corresponding author

Correspondence:

Jason D. Weber, Ph.D.

Department of Medicine

Division of Molecular Oncology


Washington University School of Medicine

660 South Euclid Avenue

Campus Box 8069


St. Louis, MO 63110 USA

Email: jweber@wustl.edu







Supplemental Figure 1:

Uncropped immunoblots associated with Figure 3A, 3C and 3D. Panels **a** and **b** are the uncropped chemiluminescence images, panels **b** and **d** are the chemiluminescence images merged with colorimetric images to show the molecular weight marker. **e** Quantification of PKR expression, PKR abundance was normalized to GAPDH and set relative shSCR.




Supplemental Figure 2:

Uncropped immunoblots for MDA-MB-468 treatment with 8-chloroadenosine (8-chloro) associated with Figure 3b, 3e and 3f. Panels **a** and **b** are the uncropped chemiluminescence images, panels **b** and **d** are the chemiluminescence images merged with colorimetric images to show the molecular weight marker. **e** Quantification of PKR expression, PKR abundance was normalized to GAPDH and set relative DMSO.







Supplemental Figure 3:

Uncropped immunoblots for HCC1806 treatment with 8-chloroadenosine (8-chloro) associated with Figure 3b, 3e and 3f. Panels **a** and **b** are the uncropped chemiluminescence images, panels **b** and **d** are the chemiluminescence images merged with colorimetric images to show the molecular weight marker.




Supplemental Figure 4:

Uncropped immunoblots for MDA-MB-468 treatment with 8-azaadenosine (8-Aza) associated with Figure 3g-3i. Panels **a** and **b** are the uncropped chemiluminescence images, panels **b** and **d** are the chemiluminescence images merged with colorimetric images to show the molecular weight marker. **e** Quantification of PKR expression, PKR abundance was normalized to GAPDH and set relative DMSO.




Supplemental Figure 5:

Uncropped immunoblots for HCC1806 treatment with 8-azaadenosine (8-Aza) associated with Figure 3g-3i. Panels **a** and **b** are the uncropped chemiluminescence images, panels **b** and **d** are the chemiluminescence images merged with colorimetric images to show the molecular weight marker.




Supplemental Figure 6:

Chromatograms for all Sanger sequencing replicates associated with Figure 4a-b.



Supplemental Figure 7:


Chromatograms for all Sanger sequencing replicates associated with Figure 4c-d.




Supplemental Figure 8:

Chromatograms for all Sanger sequencing replicates associated with Figure 4e-f.

a **MDA-MB-468**
shSCR **shADAR**




b **HCC1806**
shSCR **shADAR**




Supplemental Figure 9:

Chromatograms for all Sanger sequencing replicates associated with Figure 4g.




Supplemental Figure 10:

Chromatograms for all Sanger sequencing replicates associated with Figure 4h.




Supplemental Figure 11:

Chromatograms for all Sanger sequencing replicates associated with Figure 4i.




Supplemental Figure 12:

Chromatograms for all Sanger sequencing replicates associated with Figure 4j.




Supplemental Figure 13:

Chromatograms for all Sanger sequencing replicates associated with Figure 4k.



Supplemental Figure 14:

Chromatograms for all Sanger sequencing replicates associated with Figure 41.



Supplemental Figure 15:

a Immunoblot showing overexpression of p110 and p150 ADAR in SK-BR-3. **b** and **c** Dose response curves for 8-azaadenosine and 8-chloroadenosine in SK-BR-3 cells with (p110 or p150) or without (EV) overexpression of ADAR. In panels **b**, and **c** the large points are the mean of two independent experiments, the smaller points are the mean of three technical replicates performed for each experiment, error bars are mean \pm standard deviation.